<DOC>
	<DOCNO>NCT00434356</DOCNO>
	<brief_summary>This multicenter , Phase II , randomize , control , open label trial design provide preliminary assessment safety efficacy sunitinib combine bevacizumab paclitaxel patient previously receive chemotherapy locally recurrent metastatic breast cancer .</brief_summary>
	<brief_title>A Study Sunitinib Combination With Bevacizumab Paclitaxel Previously Untreated Patients With Metastatic Breast Cancer ( SABRE-B )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Signed Informed Consent Form Histologically cytologically confirm adenocarcinoma breast measurable nonmeasurable locally recurrent metastatic disease Age ≥ 18 year Adequate leave ventricular function study entry , define Left Ventricular Ejection Fraction ( LVEF ) &gt; 50 % either Multi Gated Acquisition ( MUGA ) scan Electrocardiogram ( ECHO ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Ability willingness comply study followup procedure Unknown HER2 status know HER2positive status Prior chemotherapy locally recurrent metastatic disease Prior hormonal therapy within 2 week prior Day 1 Prior adjuvant neoadjuvant taxane chemotherapy within 12 month prior Day 1 Prior adjuvant neoadjuvant nontaxane chemotherapy within 6 month prior Day 1 For patient receive recent radiotherapy , ongoing Grade ≥ 3 acute toxicity Patients brain metastasis full dose anticoagulation therapy Life expectancy &lt; 12 week Current , recent ( within 4 week Day 1 ) , plan participation experimental drug study Inadequate organ function within 28 day prior Day 1 Untreated abnormal thyroid function test Uncontrolled serious medical psychiatric illness Active infection require IV antibiotic enrollment randomization History malignancy within 5 year prior Day 1 except tumor negligible risk metastasis death , adequately control basal cell carcinoma squamouscell carcinoma skin carcinoma situ cervix Inadequately control hypertension Prior history hypertensive crisis hypertensive encephalopathy New York Heart Association ( NYHA ) Class II great CHF History myocardial infarction unstable angina within 12 month prior Day 1 History stroke transient ischemic attack within 12 month prior Day 1 Known central nervous system ( CNS ) disease except treated brain metastasis Significant vascular disease ( e.g. , aortic aneurysm , aortic dissection ) recent peripheral arterial thrombosis within 6 month prior Day 1 History hemoptysis within 1 month prior Day 1 Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 1 anticipation need major surgical procedure course study Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior Day 1 History abdominal fistula gastrointestinal perforation within 6 month prior Day 1 Serious , nonhealing wound , active ulcer , untreated bone fracture Proteinuria screening , demonstrate urine protein/creatinine ratio ≥ 1.0 screen Known hypersensitivity component bevacizumab sunitinib Pregnancy ( positive pregnancy test ) lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Avastin</keyword>
	<keyword>MBC</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Sutent</keyword>
</DOC>